Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Obstet Gynecol. Aug 10, 2014; 3(3): 130-133
Published online Aug 10, 2014. doi: 10.5317/wjog.v3.i3.130
Published online Aug 10, 2014. doi: 10.5317/wjog.v3.i3.130
Utility of a hemoglobin A1C obtained at the first prenatal visit
Lisa E Moore, Diana Clokey, Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, University of New Mexico, Albuquerque, NM 87131, United States
Author contributions: Moore LE designed the study, analyzed data, and wrote the paper; Clokey D recruited patients to the study, provided diabetic education to patients in the study and collected data.
Correspondence to: Lisa E Moore, MD, Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, University of New Mexico, MSC105580, Albuquerque, NM 87131, United States. lemoore@salud.unm.edu
Telephone: +1-505-2726381 Fax: +1-505-2726386
Received: March 11, 2014
Revised: May 20, 2014
Accepted: June 10, 2014
Published online: August 10, 2014
Processing time: 193 Days and 13.7 Hours
Revised: May 20, 2014
Accepted: June 10, 2014
Published online: August 10, 2014
Processing time: 193 Days and 13.7 Hours
Core Tip
Core tip: Hemoglobin A1C (HbA1C) has been endorsed by the World Health Organization for use in diagnosing diabetes and also for identifying degrees of glucose intolerance. This has not been validated in pregnancy. This study looks at a cohort of patients who received a HbA1C at the begining of pregnancy to see if the HbA1C can be used as a triaging tool for identifying patients with undiagnosed diabetes and for identifying a degree of glucose intolerance that would benefit from early intervention. HbA1C ≥ 6.5% is consistent with preexisting diabetes. HbA1C between 5.7% and 6.4% demonstrates a level of glucose intolerance associated with risk of Gestational Diabetes which may benefit from early intervention.